The observed benefits of other SGLT2 inhibitors in various neurodegenerative models suggest Enavogliflozin's potential neuroprotective properties in the context of AD pathology (Hierro‐Bujalance et al. 2020). This evidence concerns the gene SLC5A2 and Alzheimer disease.